Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1958 1
1964 2
1965 5
1966 1
1968 1
1969 3
1970 6
1971 6
1972 5
1973 3
1974 7
1975 11
1976 20
1977 11
1978 7
1979 11
1980 11
1981 17
1982 21
1983 25
1984 18
1985 21
1986 28
1987 32
1988 49
1989 72
1990 117
1991 179
1992 258
1993 336
1994 450
1995 451
1996 445
1997 433
1998 427
1999 425
2000 393
2001 356
2002 354
2003 303
2004 283
2005 300
2006 267
2007 270
2008 251
2009 240
2010 251
2011 215
2012 231
2013 265
2014 259
2015 282
2016 340
2017 352
2018 317
2019 405
2020 421
2021 426
2022 551
2023 549
2024 678
2025 728
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,353 results

Results by year

Filters applied: . Clear all
Page 1
LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics.
Tasdighi E, Adhikari R, Almaadawy O, Leucker TM, Blaha MJ. Tasdighi E, et al. Annu Rev Pharmacol Toxicol. 2024 Jan 23;64:135-157. doi: 10.1146/annurev-pharmtox-031023-100609. Epub 2023 Jul 28. Annu Rev Pharmacol Toxicol. 2024. PMID: 37506332 Free article. Review.
Lipoprotein(a) [Lp(a)] is a molecule bound to apolipoprotein(a) with some similarity to low-density lipoprotein cholesterol (LDL-C), which has been found to be a risk factor for cardiovascular disease (CVD). Lp(a) appears to induce inflam …
Lipoprotein(a) [Lp(a)] is a molecule bound to apolipoprotein(a) with some similarity to low-density lipoprotein …
Lp(a): A Rapidly Evolving Therapeutic Landscape.
Anchouche K, Thanassoulis G. Anchouche K, et al. Curr Atheroscler Rep. 2024 Nov 22;27(1):7. doi: 10.1007/s11883-024-01252-0. Curr Atheroscler Rep. 2024. PMID: 39576403 Review.
PURPOSE OF REVIEW: Elevated lipoprotein(a) (Lp[a]) is a genetically determined cardiovascular risk factor, causally linked to both atherosclerotic coronary artery disease and aortic stenosis. Elevated Lp(a) is widely prevalent, and severa …
PURPOSE OF REVIEW: Elevated lipoprotein(a) (Lp[a]) is a genetically determined cardiovascular risk factor, causa …
Lp(a): A Clinical Review.
Anchouche K, Baass A, Thanassoulis G. Anchouche K, et al. Clin Biochem. 2025 Jun;137:110929. doi: 10.1016/j.clinbiochem.2025.110929. Epub 2025 Apr 19. Clin Biochem. 2025. PMID: 40258460 Review.
Elevated lipoprotein(a) (Lp[a]) is a genetically determined cardiovascular risk factor, linked to both atherosclerotic cardiovascular disease and aortic stenosis. Elevated Lp(a) is widely prevalent, and consequently, several cardiovascula …
Elevated lipoprotein(a) (Lp[a]) is a genetically determined cardiovascular risk factor, linked to both atheroscl …
Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment.
Lampsas S, Xenou M, Oikonomou E, Pantelidis P, Lysandrou A, Sarantos S, Goliopoulou A, Kalogeras K, Tsigkou V, Kalpis A, Paschou SA, Theofilis P, Vavuranakis M, Tousoulis D, Siasos G. Lampsas S, et al. Molecules. 2023 Jan 18;28(3):969. doi: 10.3390/molecules28030969. Molecules. 2023. PMID: 36770634 Free PMC article. Review.
Lipoprotein(a) (Lp(a)) is a low-density lipoprotein (LDL) cholesterol-like particle bound to apolipoprotein(a). Increased Lp(a) levels are an independent, heritable causal risk factor for atherosclerotic cardiovascular disease (ASCVD) as …
Lipoprotein(a) (Lp(a)) is a low-density lipoprotein (LDL) cholesterol-like particle bound to apolipoprotein(a). …
A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.
Tsimikas S. Tsimikas S. J Am Coll Cardiol. 2017 Feb 14;69(6):692-711. doi: 10.1016/j.jacc.2016.11.042. J Am Coll Cardiol. 2017. PMID: 28183512 Free article. Review.
Evidence that elevated lipoprotein(a) (Lp[a]) levels contribute to cardiovascular disease (CVD) and calcific aortic valve stenosis (CAVS) is substantial. ...Recently approved proprotein convertase subtilisin/kexin-type 9 inhibitors and mipomersen lower …
Evidence that elevated lipoprotein(a) (Lp[a]) levels contribute to cardiovascular disease (CVD) and calcific aor …
Lipoprotein(a) and cardiovascular disease.
Boffa MB, Koschinsky ML. Boffa MB, et al. Biochem J. 2024 Oct 2;481(19):1277-1296. doi: 10.1042/BCJ20240037. Biochem J. 2024. PMID: 39302109 Free PMC article. Review.
Elevated plasma levels of lipoprotein(a) (Lp(a)) are a prevalent, independent, and causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease. ...In this review, we describe the salient biochemical features of Lp …
Elevated plasma levels of lipoprotein(a) (Lp(a)) are a prevalent, independent, and causal risk factor for athero …
Lipoprotein(a): from Causality to Treatment.
Kronenberg F. Kronenberg F. Curr Atheroscler Rep. 2024 Mar;26(3):75-82. doi: 10.1007/s11883-024-01187-6. Epub 2024 Jan 22. Curr Atheroscler Rep. 2024. PMID: 38252372 Free PMC article. Review.
PURPOSE OF REVIEW: This paper reviews the evidence why lipoprotein(a) (Lp(a)) is a causal risk factor for cardiovascular disease and how high Lp(a) concentrations should be managed now and with an outlook to the future. ...Lp(a …
PURPOSE OF REVIEW: This paper reviews the evidence why lipoprotein(a) (Lp(a)) is a causal risk factor for cardio …
Genetic variants associated with Lp(a) lipoprotein level and coronary disease.
Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M; PROCARDIS Consortium. Clarke R, et al. N Engl J Med. 2009 Dec 24;361(26):2518-28. doi: 10.1056/NEJMoa0902604. N Engl J Med. 2009. PMID: 20032323 Free article.
Both variants were strongly associated with an increased level of Lp(a) lipoprotein, a reduced copy number in LPA (which determines the number of kringle IV-type 2 repeats), and a small Lp(a) lipoprotein size. ...CONCLUSIONS: We identifie …
Both variants were strongly associated with an increased level of Lp(a) lipoprotein, a reduced copy number in LP …
Statins and Lp(a): The plot thickens.
Enkhmaa B, Berglund L. Enkhmaa B, et al. Atherosclerosis. 2019 Oct;289:173-175. doi: 10.1016/j.atherosclerosis.2019.07.021. Epub 2019 Aug 6. Atherosclerosis. 2019. PMID: 31443913 Free PMC article. No abstract available.
Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis.
Boffa MB. Boffa MB. Atherosclerosis. 2022 May;349:72-81. doi: 10.1016/j.atherosclerosis.2022.04.009. Atherosclerosis. 2022. PMID: 35606079 Review.
Elevated plasma concentrations of lipoprotein(a) (Lp(a)) are a causal risk factor for the development of atherothrombotic disorders including coronary heart disease. ...Accordingly, different prothrombotic mechanisms for Lp(a) must be con …
Elevated plasma concentrations of lipoprotein(a) (Lp(a)) are a causal risk factor for the development of atherot …
12,353 results
You have reached the last available page of results. Please see the User Guide for more information.